Background {#Sec1}
==========

Gay and bisexual men (GBM) are a major risk group for HIV acquisition, and are disproportionately affected by HIV in many countries \[[@CR1]\]. The rates of HIV diagnoses among GBM in high income countries including the United States (US), United Kingdom (UK), and Australia have increased over the past decade \[[@CR2]--[@CR5]\]. In Australia, annual HIV diagnoses have increased by about 70 % since 1999, and over two-thirds of new infections are diagnosed in GBM \[[@CR5]\].

Regular testing is recognised as a key strategy for HIV control. Reduction in risky sexual practices as a result of the awareness of one's HIV-positive status \[[@CR6]--[@CR8]\], and early initiation of antiretroviral therapy, can substantially reduce the risk of HIV transmission to sexual partners \[[@CR9]--[@CR11]\]. Mathematical modelling suggests that earlier diagnosis and treatment of HIV-positive individuals could substantially reduce population incidence \[[@CR12]\]. A recent trial also confirmed individual benefits with early initiation of antiretroviral therapy \[[@CR13]\]. Clinical guidelines in many countries recommend that sexually active GBM should have at least annual HIV testing, with 3--6 monthly testing for higher-risk men \[[@CR14]\].

HIV testing uptake among GBM in many middle and high income countries is lower than the recommended level \[[@CR15]--[@CR19]\], and less than a quarter of higher-risk Australian GBM test every 3--6 months consistent with the guidelines \[[@CR20]\]. Between 8 and 34 % of HIV-positive GBM in Australia \[[@CR21], [@CR22]\], New Zealand \[[@CR23]\], US \[[@CR24], [@CR25]\], UK \[[@CR18]\], and Canada \[[@CR26]\] are unaware of their HIV-positive status. Mathematical modelling suggests that individuals with undiagnosed HIV infections contribute disproportionately to HIV transmission \[[@CR27], [@CR28]\]. A number of barriers to frequent HIV testing among GBM have been identified, including: perceptions of being at low risk, fear of an HIV-positive diagnosis, no symptoms or illness, and structural barriers such as the need to return to clinics for test results, facing difficulties with appointments, lack of time, and the cost and inconvenience associated with attending clinics \[[@CR17], [@CR29], [@CR30]\].

HIV self-testing has the potential to increase testing uptake among GBM by overcoming some of the impediments to testing, particularly structural factors, improve awareness of personal HIV-status, and give a greater sense of control over men's own health \[[@CR31], [@CR32]\]. HIV self-testing kits have been approved for sale in the US \[[@CR33]\] and UK \[[@CR34]\], and other countries including France and Kenya have also changed regulations to allow self-testing for HIV \[[@CR33]\]. Australian HIV testing policy was changed in July 2014 to support self-testing for HIV, allowing manufactureres to submit applications to the Therapeutics Goods Administration for approval of self-tests \[[@CR35]\], however no self-tests have yet been approved for sale.

Surveys of GBM in Australia \[[@CR36]--[@CR40]\] and overseas indicate that men are highly interested in accessing self-testing if available \[[@CR17], [@CR41]--[@CR46]\], and likely to increase their HIV testing frequency \[[@CR47]\]. However, concerns remain about errors in interpreting test results by users, relatively lower sensitivity in early infections, emotional consequences of reactive results and access to counselling, impact on STI testing frequency, and linking people diagnosed with a self-test to care \[[@CR32], [@CR48], [@CR49]\]. HIV self-testing has been found to be highly acceptable in a range of settings and populations \[[@CR50]--[@CR52]\], with little or no evidence of harm associated with self-testing (including anxiety, fear, worry, suicide, or harm as a result of false results) \[[@CR53]\]. A high proportion of GBM in observational self-testing studies report that self-testing is easy to perform, and express willingness to test again using self-tests \[[@CR54]--[@CR58]\]. Almost all individuals (96 %) diagnosed with HIV in an unobserved field evaluation of oral fluid self-testing in the US said they would access follow-up confirmatory testing \[[@CR59]\].

An oral fluid self-test (the OraQuick In-Home HIV Test) was approved in the US on public health grounds despite its relatively lower sensitivity in the field trials \[[@CR32]\], and acute HIV infections \[[@CR60]\]. It was estimated that in the first year of its availability, 2.8 million people in the US would use the OraQuick In-Home HIV Test, and even though there would be 3800 false-negative test results (missed infections), this would be offset by 45,000 new infections being detected. Overall a reduction of more than 4000 new HIV transmissions in the first year was estimated \[[@CR32]\]. However, a subsequent modelling study predicted that if used by GBM in Seattle, HIV prevalence would increase as men would replace conventional laboratory tests at clinics with a less sensitive self-test \[[@CR61]\]. It is worth noting that the model had important limitations, for example, not including men who had not tested before and assuming men would replace their routine testing with self-tests rather than any supplementation \[[@CR62]\]. A recent analysis based on the Australian epidemic demonstrated that there would be a public health benefit (detection of HIV infections that would have otherwise remained undiagnosed) from self-testing if higher-risk GBM supplemented clinic-based testing using the OraQuick self-test or previously untested GBM used a self-test \[[@CR63]\].

To date, there is evidence from only one, as yet unpublished, randomised controlled trial (RCT) in Seattle that access to HIV self-testing increases HIV testing frequency among GBM \[[@CR47]\]. However, to our knowledge, no studies have specifically evaluated the use of HIV self-testing in GBM who test relatively infrequently or have never tested before. We describe here a randomised controlled trial which aims to assess the effectiveness and acceptability of HIV self-testing in higher-risk GBM who test more frequently (last HIV test within the past two years) and less frequently (last HIV test over two years ago or never tested before).

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a non-blinded wait-list control RCT with individuals randomised in a 1:1 ratio to two study arms: intervention (HIV self-testing) arm; and control (standard-care) arm. Participants in each arm will be followed-up for two years. Participants in the standard-care arm will switch to the self-testing arm after one year of follow-up and get access to self-testing in the second year (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Trial overview

Participants {#Sec4}
------------

Participants include two testing subgroups: those who had their last HIV test within the past two years (hereafter called 'frequent testers') and those who had their last HIV test over two years ago, or have never tested before (hereafter called 'infrequent testers').

Study objectives {#Sec5}
----------------

The primary objective of this trial is to compare HIV testing frequency between the self-testing and standard-care arms. The secondary objectives are to compare the frequency of sexually transmissible infection (STI) testing including chlamydia, gonorrhoea and syphilis between the two study arms; and to assess the reasons for HIV testing and acceptability of HIV self-testing in the self-testing arm.

Study duration {#Sec6}
--------------

The study will require 3 years to complete: 6 months for recruitment, 24 months to complete the follow-up and data collection, and 6 months for analysis and reporting.

Ethical considerations {#Sec7}
----------------------

The study protocol has been approved by the South Eastern Sydney Local Health District Human Research Ethics Committee (HREC) and the Alfred Hospital HREC. Additional ethical approvals have been obtained from Victorian AIDS Council Research Promotion and Ethics Committee, and ACON Research Ethics Review Committee.

Inclusion and exclusion criteria {#Sec8}
--------------------------------

Participants are eligible if they: identify as gay or bisexual men; are aged 18 years or above; are HIV negative (either self-reported or based on clinical records); plan to live in Australia for the next 2 years; and report any condomless anal intercourse, or \>5 male sexual partners in the past 3 months. The eligibility criteria are adopted from Australian clinical testing guidelines to recruit higher-risk GBM \[[@CR64]\], as they have the highest HIV incidence in Australia \[[@CR65]\]. Participants are excluded if they: cannot speak and/or read English; cannot provide written consent; or are unwilling or unable to comply with all the requirements of the study.

Recruitment {#Sec9}
-----------

Participants are recruited from large urban sexual health centres and community-based organisations in Sydney, Melbourne and Cairns, including: Sydney Sexual Health Centre, Melbourne Sexual Health Centre, Cairns Sexual Health Service, ACON Sydney (the largest gay men's health organisation in New South Wales), and the Victorian AIDS Council, Melbourne. Promotion of the study occurs through gay media, the study website \[[@CR66]\] and websites of participating organisations, social media (Facebook), advertisements on Grindr (a mobile device social networking application for GBM), and posters and postcards at recruitment sites. Potentially eligible participants are informed about the study by recruitment staff and clinicians. The clinical sites also use other strategies for engaging potential participants, for example: eligible participants receive a prompt when they complete a computer-assisted self-interview for routine data collection; and study nurse receives an SMS (text message) when an eligible patient completes a computer-assisted self-interview. Participants are also able to express interest in the study by completing an online form via the study website. The study coordinator assesses the information provided and refers eligible participants to the recruitment sites.

All participants are required to attend one of the study sites for recruitment. A dedicated study nurse at each clinic or a designated staff member at the community sites confirms participants' eligibility via routinely collected data on sexual behaviour or by using a paper-based eligibility screening template. Those eligible are given an information sheet, and the study procedures are explained to them. It is emphasised that the self-test is not recommended for use within three months of a potential exposure or risk event (the window period), and that reactive self-test results must be confirmed by a conventional laboratory test at a clinic. Participants are required to sign a written informed consent at recruitment covering all trial procedures and data collection.

Randomisation {#Sec10}
-------------

Computer-generated randomisation codes, stratified by testing group (frequent and infrequent testers), are produced by a biostatistician and sealed in opaque envelopes by a research assistant not associated with the trial. Once written consent is obtained, the recruitment staff select the next randomisation envelope according to the participant's testing group and inform the participant of the study arm they are being assigned to -- the self-testing or standard-care arm.

Blinding {#Sec11}
--------

Given the nature of the intervention, it is not feasible to blind the recruitment staff and participants to their study arm allocation. However, recruitment staff are unaware of the allocation until the envelope is opened in front of the participant. The statistician analysing RCT data will be blinded to the study arms.

Study procedures {#Sec12}
----------------

### Intervention (self-testing) arm {#Sec13}

Participants randomised to the self-testing arm have access to oral fluid HIV self-test kits in addition to the usual clinic-based HIV/STI testing and care. At enrolment, participants in the self-testing arm receive four self-test kits including the manufacturer-supplied step-by-step instructions and a web-link to an instructional video. Four self-test kits provide a 12 month supply for higher-risk men who test every 3--6 months consistent with the guidelines \[[@CR64]\]. Participants are able to request additional kits, one at a time, for a maximum of 12 kits in one year in case repeat testing is needed or men test more frequently in relation to risky sexual behaviour. Depending on participants' preference, additional self-test kits are either picked-up from the study sites or sent by post in plain packaging. At the beginning of the second year of follow-up, all participants (including those switching from standard-care to the self-testing arm) are eligible to collect four self-test kits from study sites, or sent by post if requested. A central log of kits dispatched is maintained to keep track of the number of kits supplied to each participant. No training on performing self-tests is provided at baseline to mimic a real-world scenario where untrained individuals will purchase self-test kits over-the-counter from pharmacies or online.

#### HIV self-testing kits {#FPar1}

The US Food and Drug Administration approved 'OraQuick In-Home HIV test' (OraSure Technologies Inc., Bethlehem, PA, USA) is being used for HIV self-testing in this study (Fig. [2](#Fig2){ref-type="fig"}). It is a second generation test which detects HIV 1/2 antibodies in oral fluid specimens. The specimen is obtained by swabbing the upper and lower gums using a collector device which is then transferred to a solution, and the results are read in 20--40 min \[[@CR59]\]. The sensitivity and specificity of the OraQuick self-test in the hands of untrained users is 91.7 % (95 % confidence interval \[CI\]: 84.2-96.3 %) and 99.9 % (95 % CI: 99.9-100.0 %), respectively \[[@CR59]\]. Every OraQuick kit is accompanied by step-by-step graphic and written instructions and two booklets with general information on HIV testing and interpretation of results. The manufacturer-specified window period for OraQuick self-test is three months \[[@CR59]\], however published data show that second generation antibody immunoassays detect HIV antibodies within 25--35 days after HIV infection \[[@CR67], [@CR68]\]. The OraQuick self-test is a preliminary test and all reactive results must be confirmed with a conventional laboratory test. As the test kit is packaged for the US market, each self-test kit supplied to participants is prominently labelled with Australian telephone numbers for support and emergencies.Fig. 2OraQuick In-Home HIV Test kit contents: instruction booklet (flipchart design), specimen collection device, developer solution vial, pre-test and post-test information booklets, pencil, and disposal bag (Source: [http://www.oraquick.com](http://www.oraquick.com/))

#### Telephone support lines {#FPar2}

A 24-h telephone support line staffed by the study coordinators on a rotation basis is available to participants, providing support for the use of self-test kits, interpretation of results, and advice for reactive home test results. In addition, participants have access to existing telephone support lines of participating sexual health centres. A log of calls to the telephone support lines is maintained and the reason for each call is recorded.

#### Follow-up of reactive self-tests {#FPar3}

Participants are advised to inform the study coordinator of any reactive self-test results. The responses to 3-monthly online questionnaires (see below) are also monitored for any reported reactive self-test results. Any participant with a reactive self-test result is advised by the study coordinator to undergo confirmatory laboratory testing and offered expedited clinical review and supportive counselling at the study clinics. If they prefer to go to a clinic other than the study clinics, they are offered assistance in arranging an appointment. The laboratory confirmation and management of participants with confirmed HIV diagnoses will be based on the standard protocols at the respective clinic, however their study involvement will cease.

### Control (standard-care) arm {#Sec14}

Participants randomised to the standard-care arm continue to access routine clinic-based HIV/STI testing and care at their preferred clinic, including clinics other than the study clinics. In Australia, most laboratories use fourth generation HIV screening immunoassays \[[@CR69]\]. Supplementary HIV antibody, HIV p24 antigen, and Western Blot testing are performed on specimens that are reactive by the screening assay, and deemed positive if consistent with the national case definition \[[@CR70]\]. After 12 months, participants in the standard-care arm switch to the self-testing arm and follow the same procedures as the self-testing arm.

Outcome measures {#Sec15}
----------------

The primary outcome is the mean number of HIV tests per person over 12 months. The secondary outcomes are: the mean number of STI (chlamydia, gonorrhoea, syphilis) tests per person; reasons for HIV testing; and the acceptability of HIV self-testing.

Data collection {#Sec16}
---------------

### Clinical data {#Sec17}

HIV and STI testing data for the duration of the study will be extracted from the patient management system for all participants recruited at study clinics.

### Surveys {#Sec18}

#### Baseline {#FPar4}

All participants complete a self-administered online survey on a handheld electronic device at enrolment. The survey covers socio-demographics, sexual risk behaviour, HIV/STI testing history, attitudes to HIV self-testing, opinions about treatments for HIV, and an HIV testing self-efficacy scale measuring gay men\'s confidence in their ability to undertake HIV testing \[[@CR71]\].

#### 3-monthly {#FPar5}

Participants in both arms of the study complete a brief online survey every three months asking the number, location, reasons for, and results of HIV self-tests and HIV/STI tests at clinics and community sites, and sexual risk behaviour since their last survey. Participants are also asked about the number of self-test kits they used to test their sexual partner(s) or gave to someone else to test at another time. If participants report episodes of HIV/STI testing at clinics other than study clinics, those clinics are contacted to obtain test results. Consent for release of results is obtained at enrolment and mailed/faxed to relevant clinics when obtaining results.

#### 12 months {#FPar6}

At 12 months, a survey is conducted including the same questions as the 3-monthly survey with some additional questions about self-testing acceptability, ease of use overall and for various steps of HIV self-testing, participants' experience using self-tests to test themselves and their partner(s), if relevant, and their preferences for accessing and using HIV self-testing in the future.

### Survey reminders {#Sec19}

If participants have not completed a survey, they are sent up to three reminders via email or SMS, each one week apart. If surveys are not completed after three reminders, participants are sent a final SMS asking the total number of HIV tests and the number of HIV self-tests since their last survey.

### In-depth interviews {#Sec20}

About 25 participants in the self-testing arm will be invited to participate in a face-to-face semi-structured in-depth interview at the completion of 12 months follow-up. Participants are asked at enrolment if they are willing to be contacted for in-depth interviews. The interviews will focus on collecting detailed information about their HIV testing pattern prior to the study, their experience using self-tests to test themselves and their partner(s) during the study, any changes in their testing patterns and sexual behaviour after getting access to self-testing, and their opinions about HIV self-testing in the future. Participants from each of the following groups will be interviewed: those who tested themselves using self-tests only; those who tested at clinics and supplemented their testing with self-tests; those who tested their partner(s) using self-tests; and those who had a confirmed positive or false-reactive self-test result.

Statistical analysis plan {#Sec21}
-------------------------

All analyses will be conducted using Stata 14. The mean HIV and STI testing frequency in each arm (self-testing and standard-care) by testing subgroup (frequent and infrequent testers) will be assessed using an intention-to-treat analysis at 12 months. The per-protocol analyses will include calculating: (i) the reasons for HIV testing; and (ii) the acceptability of HIV self-testing in the self-testing arm.

The mean HIV testing frequency per person in the first 12 months will be calculated, excluding any tests performed at enrolment. Only self-reported HIV tests where there is a record of an HIV test occurring at a clinic or community site will be included. The following tests will be excluded from the testing frequency calculation: HIV self-tests where participants did not obtain a result for any reason; self-test kits used to test a partner(s) or given to someone else; and confirmatory HIV tests following a reactive self-test. STI testing will include episodes of testing for chlamydia, gonorrhoea, or syphilis tests, and will be included where there is a record of a test occurring at a clinic or community site.

The effects of the intervention will be measured by comparing the mean HIV testing frequency, the mean STI testing frequency, and mean clinic-based HIV tests in each arm by testing subgroup using a *t*-test. The reasons for self-tests and clinic tests in the self-testing arm will be compared using repeated measures logistic regression clustered on individual. The acceptability analysis will be descriptive only. Differences in proportions will be investigated using Chi^2^ statistics.

Sample size {#Sec22}
-----------

In the analysis, we intend to assess the primary outcome for the frequent and infrequent testers subgroups and overall. For frequent testers, a sample size of 112 in each arm will detect an increase in HIV testing frequency from 1.5 tests per year to 2 tests per year (standard deviation \[SD\]: 2.4) with 80 % statistical power and type I error probability of 0.05. The frequency of 1.5 tests per year is based on the results of a previous clinic based RCT in Melbourne \[[@CR72]\], and data from Australian sexual health clinics \[[@CR73]\]. For infrequent testers, a sample size of 14 in each arm will detect an increase in HIV testing frequency from 0.2 tests per year (assuming one HIV test in the past five years based on clinic data \[[@CR73]\]) to 1 test per year (SD: 0.7) with 80 % statistical power and type I error probability of 0.05. On this basis, we conservatively estimate a sample size of 300 frequent testers and 50 infrequent testers for an overall sample size of 350. The sample size of 350 will achieve at least 80 % statistical power to detect an overall increase from 1.5 to 2 tests per year (SD: 2.4) for the two groups combined.

Trial registration {#Sec23}
------------------

The trial is registered with the Australian and New Zealand Clinical Trial Registry \[trial ID: ACTRN12613001236785, registered on November 12, 2013\].

Discussion {#Sec24}
==========

Gay and bisexual men are at an increased risk of acquiring HIV infection, and the rates of HIV diagnoses in GBM have increased in recent years. Yet, the uptake of HIV testing among GBM in Australia and other countries is lower than the recommended level, and a significant proportion of HIV infections remain undiagnosed. HIV self-testing has the potential to improve testing uptake and frequency among GBM. To our knowledge, the FORTH trial is the first in Australia to assess whether access to HIV self-testing increases HIV testing frequency among GBM, and the first internationally among GBM who test less frequently or have never tested before.

A major strength of the FORTH trial is the focus on infrequent testers. A recent Australian study showed that in addition to GBM using self-tests to supplement their existing testing, there will be a public health benefit if previously untested GBM test for the first time using HIV self-tests \[[@CR63]\]. In Australia, about 20 % of GBM in community-based samples reported their last HIV test was over two years ago or have never tested for HIV \[[@CR19]\]. In 2011, about 17 % of GBM in six US cities reported they had never tested before for HIV \[[@CR17]\]. An RCT in Seattle showed that access to HIV self-testing significantly increased HIV testing frequency among GBM over a 15 months period (3.6 vs. 5.3 tests per person) \[[@CR47]\], however the study did not specifically explore the outcomes in infrequent testers. In addition, there are other methodological differences: our sample size is larger (350 vs. 230); follow-up duration is longer (24 months vs. 15 months) allowing us to assess the sustainability of the intervention; and the wait-list design will allow us to assess the impact of delayed access to self-testing on HIV testing frequency.

An important consideration when GBM start using self-tests is whether they supplement or replace their routine testing with self-tests \[[@CR37]\]. Though cross-sectional surveys of Australian GBM indicate that they are likely to test more often if self-testing is available \[[@CR36]\], our study will provide conclusive evidence as to whether access to HIV self-testing among GBM: increases testing frequency, and to a level where a public health benefit can be achieved \[[@CR63]\]; leads men to supplement or replace their existing testing; and leads untested men to test for HIV for the first time. Also, the findings will improve our understanding of the reasons for self-testing among GBM, and whether men use self-tests to test themselves after risk events. We are also asking participants about their preferences for future self-testing delivery methods including online, pharmacy, and clinics, to understand how men would prefer to access self-testing when available.

A major concern in relation to HIV self-testing is that it may lead to GBM testing less frequently for other STIs including chlamydia, gonorrhoea and syphilis, for which they would still need to attend clinics. The prevalence of STIs is high in GBM, and repeat rectal chlamydia and gonorrhoea infections have been associated with an increased risk of HIV seroconversion \[[@CR74]\]. Our study will be able to assess whether access to HIV self-testing will lead to a lower STI testing frequency in GBM.

Previous studies have indicated that GBM are willing to use self-tests to test partners before sexual intercourse, and there is potential for detecting undiagnosed infections \[[@CR75]\]. Although not a main outcome of this study, we are collecting information about the number of self-test kits participants used to test their partners and the type of partners they tested. This will be further explored in in-depth interviews to contextualise the use of self-tests with partners, for example, whether men use self-tests to negotiate safe sex, make decisions to have sex without condoms and so on.

The study will contribute to the scarce literature internationally on the impact of self-testing on HIV testing frequency among GBM. The study will provide evidence on the level of testing that could be achieved with HIV self-testing among Australian GBM, and whether men supplement or replace their existing testing with self-testing. The findings will improve our understanding of the safety, effectiveness and acceptability of self-testing, particularly among infrequent testers. The findings will have important implications for self-testing policy, both in Australia and internationally.
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